48.235958, 9.875466
PDF / print export
Rentschler Biopharma
Laupheim, Germany
- Verified lead
- Prof. Dr. Uwe Bücheler
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- Interim Chief Executive Officer
- 2026 technical specialization
- Mammalian Biologics CDMO, Late-Stage Development, and Commercial Manufacturing
- Review cycle
- May 2026
- Full address
- Erwin-Rentschler-Str. 21, 88471 Laupheim, Germany
- Site coordinates
- 48.235958, 9.875466
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Rentschler management-team page confirming Prof. Dr. Uwe Bücheler as interim CEO.
- Editorial note
- Clinical-to-commercial biologics campus with mammalian suites, bioreactor trains, and FDA/EMA-facing analytical release infrastructure.
Mammalian Biologics CDMO, Late-Stage Development, and Commercial Manufacturing
GMP biologics manufacturing, Global quality and regulatory systems
Clinical-to-commercial biologics campus with mammalian suites, bioreactor trains, and FDA/EMA-facing analytical release infrastructure.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Clinical-to-commercial biologics campus with mammalian suites, bioreactor trains, and FDA/EMA-facing analytical release infrastructure.
- Lead
- Prof. Dr. Uwe Bücheler (verified ↗)
- Address
- Erwin-Rentschler-Str. 21, 88471 Laupheim, Germany (source ↗)
- Compliance
- GMP biologics manufacturing
- Last reviewed
- 14 Mar 2026 (3mo ago)
- Scale
- Clinical-to-commercial CDMO manufacturing
- Capabilities
- Mammalian Cell Culture · Process Development · Commercial Biologics Manufacturing
- Founded
- 1872
- Headcount
- 1001-5000
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED MARCH 2026
Prof. Dr. Uwe Bücheler
Interim Chief Executive Officer
Full addressErwin-Rentschler-Str. 21, 88471 Laupheim, Germany
Site coordinates48.235958, 9.875466
Review cycleMay 2026
Physical site source
Official Rentschler Biopharma contact page listing Erwin-Rentschler-Str. 21, Laupheim.
Open sourceClinical-to-commercial CDMO manufacturing
Laupheim, Germany. Mammalian Biologics CDMO, Late-Stage Development, and Commercial Manufacturing. Review completed on 14 Mar 2026.
German, EMA, FDA, and global biologics oversight
GMP biologics manufacturing, Global quality and regulatory systems
Mammalian Biologics CDMO, Late-Stage Development, and Commercial Manufacturing
Clinical-to-commercial biologics campus with mammalian suites, bioreactor trains, and FDA/EMA-facing analytical release infrastructure.
Related companies
Editorial note
Rentschler is published with the current interim-CEO state rather than the outgoing leadership name, matching the official January 2026 management surface.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Mammalian Cell Culture
Process Development
Commercial Biologics Manufacturing
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Mammalian production suites
Bioreactor trains
Analytical quality laboratories
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- VERIFIED ACTIVE 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- VERIFIED ACTIVE 2026
Verification history
Verification history
14 Mar 2026: Executive identity confirmed via official management disclosure.
14 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Rentschler Biopharma located?
- Rentschler Biopharma operates from Erwin-Rentschler-Str. 21, 88471 Laupheim, Germany, Laupheim, Germany.
- Who runs Rentschler Biopharma?
- Rentschler Biopharma is led by Prof. Dr. Uwe Bücheler, Interim Chief Executive Officer. Verified 14 Mar 2026.
- What certifications does Rentschler Biopharma hold?
- Rentschler Biopharma is documented under GMP biologics manufacturing.
- What does Rentschler Biopharma do?
- Clinical-to-commercial biologics campus with mammalian suites, bioreactor trains, and FDA/EMA-facing analytical release infrastructure. Core capabilities: Mammalian Cell Culture, Process Development, Commercial Biologics Manufacturing.
Editorial context
Related technical briefs
Briefs that name Laupheim as a covered market or city.